skip to content


Abzena licensing deal with Trieza

22 December 2016 07:37

Abzena has signed a licence agreement with Trieza Therapeutics, a start-up biotechnology company specialising in the discovery and development of immunomodulatory oncolytic viruses.

Abzena has granted Trieza an exclusive worldwide, royalty bearing, sub-licensable licence to an undisclosed antibody sequence, which was created using the Group's Composite Human Antibody technology, for exploitation in conjunction with Trieza's viral vector technology to develop novel therapies in oncology.

Abzena could receive up to $35m in development and commercial milestone payments as well as royalties on the sale of licensed products containing the Abzena sequence.

Story provided by

Related Company: ABZA

Info Point:

To buy or sell shares call our Dealing Room on 0113 243 6941.

Too much jargon? Our glossary will help make sense of things.

Find out more about our Share Dealing Services.

Client Area Access

» Secure Login

» Not registered yet?

Bluezest Aviva Aberdeen

Branch Finder

Redmayne-Bentley have High Street branches throughout the UK. Find your nearest branch.